Hepatitis A and B vaccination

The rate of uptake and course completion in patients with hepatitis C

Trinity Fredericks
Kellie Kwan
Donna Mak

Background
Western Australian general practitioners may order Department of Health funded hepatitis A and B vaccines for patients newly notified with hepatitis C to prevent complications associated with coinfections. The aim of this study was to determine vaccination uptake of hepatitis C patients through this program.

Methods
We reviewed hepatitis C notifications and hepatitis A and B vaccine orders received in 2007 and 2008 to determine the rate of vaccine uptake and course completion.

Results
Vaccination orders for initial doses were received for 37% (448/1209) of patients. Vaccination uptake was positively associated with age and non-Aboriginality. Final vaccination doses were ordered for 30% of patients for whom an initial order had been received.

Discussion
Uptake of hepatitis A and B vaccination was higher than that of similar populations. However, vaccination course completion was low. General practitioners need to emphasise to their patients the importance of completing a vaccine course.

Keywords: hepatitis C; immunisation; primary prevention

Hepatitis C virus (HCV) is one of the most commonly reported infectious diseases in Australia and represents a major public health concern. In the 16 year period from 1990 to 2005, over 225 000 people in Australia tested positive for hepatitis C antibodies. There are an estimated 8000–12 000 new HCV infections annually, of which are attributed to injecting drug use. Injecting drug users are also at higher risk of exposure to hepatitis B virus (HBV) due to common risk factors and modes of transmission.

Several systematic literature reviews show that acute or chronic HBV and/or acute hepatitis A (HAV) infection superimposed on chronic HCV is associated with a more severe clinical course, including higher mortality rates. As both these infections are vaccine preventable, the National Health and Medical Research Council, along with numerous international health authorities, recommended vaccinating patients with HCV against these viruses.

Previous studies of HAV and HBV vaccination in patients with HCV show that adherence to recommendations is low, ranging from 0–27%. Shim et al. found that only 26.8% of susceptible patients infected with chronic HCV had received vaccination for HAV. In this study, three of the unvaccinated patients developed acute HAV infections during follow up, one of whom died due to acute liver failure. In addition to a low vaccination rate, studies have shown that serial vaccination completion among HCV patients ranges from 35–72%.

In 2005, the Western Australian Department of Health (DoH) established a program aimed at increasing the accessibility of HAV and HBC vaccines among adults at high risk. One component of this program allows GPs and primary health care providers (collectively termed GPs) to order DoH funded vaccines for patients newly notified with HCV on or after 1 September 2005. On receipt of a new HCV notification, DoH sends the notifying GP a personalised vaccine order form for that patient. Notifying doctors who are not GPs are asked to refer the patient to a GP for vaccination.

Four vaccination schedules are available as part of the program:

- standard schedule – combined HAV and HBV vaccine: 0, 1 and 6 months (order initial two doses and final dose after 5–6 months)
- accelerated schedule – combined HAV and HBV vaccine: 0, 7, 21 days and 12 months (order initial three doses and final dose after 11–12 months)
- hepatitis A vaccine – patient known hepatitis B carrier/immune: 0 and 6 months (order initial dose and final dose after 5–6 months)
- hepatitis B vaccine – patient known hepatitis A immune: 0, 1 and 6 months (order initial two doses and final dose after 5–6 months).

This study aimed to determine the rate of uptake and vaccine order completion of HAV and HBV vaccinations among patients newly notified with HCV in Western Australia by GPs between 1 January 2007 and 31 December 2008.

Methods
The total number of HCV notifications from 1 January 2007 to 31 December 2008 was obtained from the Western Australia Notifiable Infectious Disease Database. The hepatitis A and hepatitis B vaccination order database, established on 1 September 2005, contains the name and demographic details of patients notified with HCV and their notifying doctor, along with the corresponding vaccination order details. From this database, we extracted data for all patients notified with HCV by GPs from 1 January 2007 to 31 December 2008. Data were extracted in August 2009. Multiple vaccination orders for the same patient and patients for whom vaccination...
orders forms were not sent due to program ineligibility or incorrect doctor’s address, were removed before analysis.

Data were analysed using SPSS version 17.0 (SPSS Inc., Chicago, IL). Vaccine uptake was estimated by calculating the proportion of patients notified with HCV for whom an initial vaccine order had been received. The median and range of the time interval between the vaccination order form being sent to the notifying doctor and the order being received at DoH, and between initial and final vaccination orders, were also calculated. Chi-square analyses were used to examine differences in ordering patterns based on age, race and gender.

**Results**

**Demographic features**

During the 2 year study period, a total of 1209 HCV notifications were received from GPs, representing over 55% of the total number of HCV notifications received in Western Australia. The median age of patients was 39 years (range 0–89 years); 57% were male; 80% were from the metropolitan region; 74% were non-Aboriginal; 6% were identified as Aboriginal, and 20% had an unknown Aboriginal status.

**Initial vaccine order**

Overall, initial vaccination doses were ordered for 448 patients (37%). Older patients ($\chi^2$ test for trend $p=5.38; df=1; p<0.02$), non-Aboriginal patients and those of unknown Aboriginality were more likely to have had initial vaccine doses ordered (Table 1). The standard schedule of combined HAV and HBV vaccine comprised 70% of vaccine orders (Table 2).

**Vaccination order completion**

Overall, the completion of vaccination orders was low, with only 30% of patients having had the final vaccination dose ordered (Table 1). A final vaccine dose was more likely to be ordered for patients for whom the standard initial schedules were ordered (32–38%) compared with those for whom an accelerated schedule was ordered (12%) (Table 2).

**Discussion**

We estimated vaccine uptake by measuring the proportion of patients for whom an initial vaccine order had been received. Some patients may not have received their initial vaccine dose, so this method may overestimate vaccine uptake. However, given that GPs were required to complete a personalised order form for that patient, it seems likely that they would take reasonable steps to administer the vaccine to that particular patient. Conversely, we have assumed that patients are not protected against HAV and/or HBV unless we received both initial and final vaccine orders for them. However, if the patient was known to be immune to HAV and/or HBV or had been partially vaccinated, their GP is unlikely to have ordered any vaccines or a complete vaccine course, respectively.

The demographic distribution recorded for patients in this study was similar to that of Australian HCV patients.14

Vaccine uptake of patients of unknown Aboriginality was similar to those of non-Aboriginal patients. This was probably because patients in Western Australia notified with HCV and of unknown Aboriginality are far more likely to be non-Aboriginal than Aboriginal.15

The vaccine uptake observed in this study (37%) was higher than any previously reported, including a recent retrospective study of 243 HCV patients notified with HCV for whom an initial vaccine order was placed who also had a final vaccine dose ordered (eg. male = 285/686 x 100 = 37.2%)}

**Table 1. Vaccination ordering rates for initial vaccine doses and the final vaccine dose, by patient demographics, 1 January 2007 to 31 December 2008**

<table>
<thead>
<tr>
<th>Demographic features</th>
<th>Initial dose</th>
<th>Final dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>%</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (n=686)</td>
<td>255</td>
<td>37.2</td>
</tr>
<tr>
<td>Female (n=523)</td>
<td>193</td>
<td>36.9</td>
</tr>
<tr>
<td>Age group (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20 (n=25)</td>
<td>5</td>
<td>20.0</td>
</tr>
<tr>
<td>20–29 (n=232)</td>
<td>76</td>
<td>32.8</td>
</tr>
<tr>
<td>30–39 (n=337)</td>
<td>129</td>
<td>38.3</td>
</tr>
<tr>
<td>40–49 (n=333)</td>
<td>121</td>
<td>36.3</td>
</tr>
<tr>
<td>50+ (n=282)</td>
<td>117</td>
<td>41.5</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metropolitan (n=972)</td>
<td>366</td>
<td>37.7</td>
</tr>
<tr>
<td>Nonmetropolitan (n=237)</td>
<td>82</td>
<td>34.6</td>
</tr>
<tr>
<td>Aboriginality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aboriginal (n=70)</td>
<td>16</td>
<td>22.9</td>
</tr>
<tr>
<td>Non-Aboriginal (n=898)</td>
<td>355</td>
<td>39.5</td>
</tr>
<tr>
<td>Unknown (n=241)</td>
<td>77</td>
<td>32.0</td>
</tr>
</tbody>
</table>

* Percentage refers to the percentage of patients of a particular demographic feature for whom an initial vaccine order was placed (eg. male = 285/686 x 100 = 37.2%)

**Table 2. Distribution of vaccination type among patients for whom initial vaccine doses and the final vaccine dose were ordered, 1 January 2007 to 31 December 2008**

<table>
<thead>
<tr>
<th>Vaccination type</th>
<th>Initial doses</th>
<th>Final dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number</td>
<td>%</td>
</tr>
<tr>
<td>Standard hepatitis A and hepatitis B schedule</td>
<td>314</td>
<td>70.1</td>
</tr>
<tr>
<td>Hepatitis A vaccine only</td>
<td>53</td>
<td>11.8</td>
</tr>
<tr>
<td>Hepatitis B vaccine only</td>
<td>16</td>
<td>3.6</td>
</tr>
<tr>
<td>Accelerated hepatitis A and hepatitis B schedule</td>
<td>65</td>
<td>14.5</td>
</tr>
<tr>
<td>Total</td>
<td>448</td>
<td>100</td>
</tr>
</tbody>
</table>

* Note: Percentages don’t add up to 100 because they refer to the percentage of patients for whom an initial vaccine order was placed who also had a final dose ordered (eg. standard schedule = 108/314 x 100 = 32.8%)
infected patients where only 8% and 9% of patients diagnosed from 2000 to 2005 received HAV or HBV vaccination respectively. Although we cannot be certain about the cause of this observation, we did not collect data from patients and doctors about the reasons behind their decision making, it seems reasonable to assume that elimination of some previously identified obstacles to vaccination, including the burden of vaccination cost and practitioner knowledge of the importance of vaccination, was a contributing factor. Low vaccination order rates among Aboriginal (23%) and younger patients (20% in patients aged <20 years) may indicate that the program was less effective at eliminating obstacles to vaccination in these groups and/or be a reflection of their relatively low levels of access to, and use of, GP services.

Although vaccine uptake was higher than that reported elsewhere, vaccine course completion was low. Only 30% of those patients who had an initial dose ordered also had a final dose ordered. This vaccine order completion rate is similar to that found by Macdonald et al. who reported a 21% completion rate among ‘at risk’ adults treated at primary healthcare centres in Sydney (New South Wales). However, they were considerably lower that the previously mentioned study by Rachem et al. who reported that 65–72% of HCV patients completed their vaccine course. Previous studies evaluating the immunogenic response to HBV vaccines in healthy adults reported a seroprotection response of approximately 78% after administration of the second dose of vaccine, which increases to 98% after the final dose.

The percentage seroconversion reported for HAV vaccine was 99% after the second dose of Twinrix (combined HAV and HBV vaccine) and almost 100% upon serial completion. However, in HCV infected patients, several studies suggest a lower and highly variable immunogenic response rate to HAV and HBV vaccination, which is further diminished in those with advanced or decompensated liver disease. Therefore, vaccine course completion in HCV infected individuals is important to ensure adequate protection against HAV and HBV infections. The literature has suggested that the provision of an accelerated vaccination schedule would improve both patient and physician compliance and improve vaccine course completion. However, in the current study we found that the provision of an accelerated schedule of Twinrix resulted in a significantly lower vaccination order completion rate than the standard schedule of Twinrix and HAV and HBV vaccination alone. This may be because the accelerated schedule is recommended for high risk patients in whom compliance may be a problem.

**Conclusion**

The provision of free HAV and HBV vaccines to patients diagnosed with HCV in Western Australia was associated with higher vaccination rates among GPs to those previously reported. However, the low vaccination order completion rate observed in this study was reflective of rates previously reported in similar populations and indicates the need for doctors to emphasise to their patients the importance of completing a vaccine course.

**Authors**

Trinity Fredericks BSc(Hons) is a program officer, Sexual Health and Blood-borne Virus Program, Communicable Disease Control Directorate, Health Department of Western Australia.

Kellie Kwan BA(Hons), GradCertAppEpi, is Senior Research Officer, Communicable Disease Control Directorate, Health Department of Western Australia.

Donna Mak MBBS, MPH, FAPHM, FACRRM, is a public health physician, Communicable Disease Control Directorate, Health Department of Western Australia, and Head, Population & Preventive Health, University of Notre Dame, Fremantle, Western Australia.

Conflict of interest: none declared.

**Acknowledgments**

We would like to acknowledge the work done by staff at the Communicable Disease Control Directorate and Western Australian general practices in the implementation of the hepatitis A and B vaccination program.

**References**

14. Western Australian Department of Health. The epidemiology of notifiable sexually transmitted infections and blood-borne viruses in Western Australia 2005–2007. Available at [www.public.health.wa.gov.au/cproot/685/2/2005%20%20%20Notifiable%20STIs%20and%20%20BBVs%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%2